Regulatory Strategy Discussion
A focused advisory session for MedTech teams navigating regulatory, portfolio, or market-access decisions under EU MDR, IVDR, UK regulation, or emerging AI Act obligations.
Depending on your situation, the discussion may focus on technical documentation, clinical evidence strategy, post-market obligations, product classification, market access planning, or regulatory implications for transactions, diligence, and portfolio risk.
In this session, we typically:
Identify gaps in clinical evaluation, performance evaluation, or post-market surveillance strategy,
Flag issues in CER, PER, PMS or PMCF documentation that may create regulatory or transaction risk,
Clarify classification, market scope, approval pathways, or lifecycle obligations,
Assess audit readiness, remediation exposure, or evolving MDR/UK regulatory expectations, or
Pressure-test strategic decisions relating to submissions, product changes, market access, or diligence activity.
This discussion is designed for regulatory leaders, founders, legal teams, investors, and MedTech organisations who need a clearer understanding of regulatory exposure, evidence strategy, or market-access risk.
Your session will be led by Alastair Selby, Managing Consultant at SciMed Consultancy Ltd.
You’ll leave with a clearer understanding of the key regulatory issues, where the pressure points sit, and what practical next steps make sense.
If you’re not ready to schedule a call, you can submit a regulatory enquiry instead.